Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of (S)-Modafinil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 known ✓ | Q01959 | 3/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.43 |
| ▸ | DRD3 | P35462 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | EDNRB | P24530 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MC4R | P32245 | 1/20 | 0.43 |
| ▸ | MC3R | P41968 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 2/20 | 0.39 |
| ▸ | CES1 | P23141 | 2/20 | 0.39 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Modafinil SCHEMBL3238686 | 1.00 | CYP2D6 (0.44) | CYP2D6CYP1A2PKMSMN1; SMN2NPSR1 | |
| Modafinil SCHEMBL34488 | 1.00 | CYP2D6 (0.44) | CYP2D6CYP1A2PKMSMN1; SMN2NPSR1 | |
| Modafinil SCHEMBL1560974 | 1.00 | CYP2D6 (0.44) | CYP2D6CYP1A2PKMSMN1; SMN2NPSR1 | |
| Armodafinil SCHEMBL34489 | 1.00 | CYP2D6 (0.44) | CYP2D6CYP1A2PKMSMN1; SMN2NPSR1 | |
| Modafinil SCHEMBL3908867 | 0.96 | EPHX1 (0.42) | CYP2D6CYP1A2PKMSMN1; SMN2NPSR1 | |
| Modafinil SCHEMBL19025521 | 0.95 | PKM (0.41) | CYP2D6CYP1A2PKMSMN1; SMN2NPSR1 | |
| Modafinil SCHEMBL193837 | 0.95 | CYP2D6 (0.41) | CYP2D6CYP1A2PKMSMN1; SMN2NPSR1 | |
| Modafinil SCHEMBL3914634 | 0.95 | PKM (0.41) | CYP2D6CYP1A2PKMSMN1; SMN2NPSR1 | |
| Modafinil SCHEMBL3921259 | 0.95 | PKM (0.41) | CYP2D6CYP1A2PKMSMN1; SMN2NPSR1 | |
| Modafinil SCHEMBL4957995 | 0.93 | CYP1A2 (0.40) | CYP2D6CYP1A2PKMSMN1; SMN2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214862-A1 | Processes for preparing armodafinil intermediate | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-09-04 | — | — | US | claimed |
| WO-2008070143-A1 | PROCESSES FOR PREPARING ARMODAFINIL INTERMEDIATE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-06-12 | — | — | WO | claimed |
| US-12344866-B2 | Biocatalysts and methods for the synthesis of armodafinil | CODEXIS, INC. (US) | 2025-07-01 | — | — | US | disclosed |
| CN-117303992-A | Preparation method of polyfunctional group substituted chiral sulfoxide compound | 厦门大学 | 2023-12-29 | — | — | CN | disclosed |
| CN-115835862-A | Combination for treating alzheimer's disease and use thereof | 广州新创忆药物临床研究有限公司 | 2023-03-21 | — | — | CN | disclosed |
| US-20220372452-A1 | BIOCATALYSTS AND METHODS FOR THE SYNTHESIS OF ARMODAFINIL | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2022-11-24 | — | — | US | disclosed |
| US-11384343-B2 | Biocatalysts and methods for the synthesis of armodafinil | CODEXIS, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-10710061-B2 | Ion pair catalysis of tungstate and molybdate | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2020-07-14 | — | — | US | disclosed |
| US-10710061-B2 | Ion pair catalysis of tungstate and molybdate | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2020-07-14 | — | — | US | disclosed |
| US-20190105646-A1 | ION PAIR CATALYSIS OF TUNGSTATE AND MOLYBDATE | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2019-04-11 | — | — | US | disclosed |
| US-20190105646-A1 | ION PAIR CATALYSIS OF TUNGSTATE AND MOLYBDATE | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2019-04-11 | — | — | US | disclosed |
| US-20090018202-A1 | Modafinil compositions | CEPHALON, INC. (US) | 2009-01-15 | — | — | US | disclosed |
| WO-2008149141-A2 | NOVEL PROCESS | GENERICS [UK] LIMITED (GB) | 2008-12-11 | — | — | WO | disclosed |
| WO-2008149141-A2 | NOVEL PROCESS | GENERICS [UK] LIMITED (GB) | 2008-12-11 | — | — | WO | disclosed |
| US-7368591-B2 | Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation | CEPHALON FRANCE (FR) | 2008-05-06 | — | — | US | disclosed |
| WO-2007027328-A2 | MICROBIAL SULFOXIDATION AND AMIDATION OF BENZHDRYLSULFANYL CARBOXYLIC ACIDS AND USES THEREOF | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2007-03-08 | — | — | WO | disclosed |
| US-20070026507-A1 | MICROBIAL SULFOXIDATION AND AMIDATION OF BENZHDRYLSULFANYL CARBOXYLIC ACIDS AND USES THEREOF | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2007-02-01 | — | — | US | disclosed |
| US-20070026507-A1 | MICROBIAL SULFOXIDATION AND AMIDATION OF BENZHDRYLSULFANYL CARBOXYLIC ACIDS AND USES THEREOF | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2007-02-01 | — | — | US | disclosed |
| US-20070026507-A1 | MICROBIAL SULFOXIDATION AND AMIDATION OF BENZHDRYLSULFANYL CARBOXYLIC ACIDS AND USES THEREOF | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2007-02-01 | — | — | US | disclosed |
| US-20070021510-A1 | Modafinil compositions | CEPHALON, INC. (US) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214862-A1 | Processes for preparing armodafinil intermediate | CYP3A4, CYP7A1, CYP2B6 | SLC6A3 2269/4885CYP2D6 8/4885CYP1A2 6/4885 |
| US-10710061-B2 | Ion pair catalysis of tungstate and molybdate | PRDX3, PRDX4, PRDX2 | SLC6A3 123/4885CYP2D6 139/4885CYP1A2 1800/4885 |
| US-20190105646-A1 | ION PAIR CATALYSIS OF TUNGSTATE AND MOLYBDATE | PRDX3, PRDX4, PRDX6 | SLC6A3 103/4885CYP2D6 124/4885CYP1A2 1967/4885 |
| US-20070021510-A1 | Modafinil compositions | CYP3A4, COMT, CYP3A43 | SLC6A3 58/4885CYP2D6 5/4885CYP1A2 46/4885 |
| US-20090018202-A1 | Modafinil compositions | COMT, GRIN3A, EPM2A | SLC6A3 46/4885CYP2D6 23/4885CYP1A2 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.